Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Earnings for Geron Corporation (GERN)
Earnings in 2023 (TTM): $-184,127,000
According to Geron Corporation's latest financial reports the company's current earnings (TTM) are $-184,127,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Geron Corporation
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-184,127,000 | $-184,127,000 |
| 2022 | $-141,901,000 | $-141,033,000 |
| 2021 | $-116,112,000 | $-120,952,000 |
| 2020 | $-75,617,000 | $-75,610,000 |
| 2019 | $-68,548,000 | $-63,551,000 |
| 2018 | $-27,017,000 | $-27,017,000 |
| 2017 | $-27,916,000 | $-27,916,000 |
| 2016 | $-29,537,000 | $-29,537,000 |
| 2015 | $46 K | $46 K |
| 2014 | $-35,670,000 | $-35,670,000 |
| 2013 | $-38,379,000 | $-38,379,000 |
| 2012 | $-68,881,000 | $-68,881,000 |
| 2011 | $-96,853,000 | $-96,853,000 |
| 2010 | $-111,377,000 | $-111,377,000 |
| 2009 | $-70,184,000 | $-70,184,000 |
| 2008 | $-62,021,000 | $-62,021,000 |
| 2007 | $-36,697,000 | $-36,697,000 |
| 2006 | $-31,365,000 | $-31,365,000 |
| 2005 | $-33,528,000 | $-33,528,000 |
| 2004 | $-80,405,000 | $-80,405,000 |
| 2003 | $-29,883,000 | $-29,883,000 |
| 2002 | $ | $-33,908,000 |
| 2001 | $-46,929,000 | $-42,073,000 |
| 2000 | $ | $-45,833,000 |
| 1999 | $-44,200,000 | $-46,400,000 |
| 1998 | $-9,900,000 | $-10,800,000 |
| 1997 | $-9,100,000 | $-9,600,000 |
| 1996 | $-10,400,000 | $-10,700,000 |